Skip to main content

September 2022, Vol 12, No 9

In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms. Read More ›

Based on their anatomic site of origin, cholangiocarcinomas (CCAs) are classified as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Read More ›

It is common for employees in the healthcare industry to begin their careers in entry-level positions and then move on to other positions as they acquire on-the-job training and experience. However, additional education and training is often necessary to ensure that their skills match an organization’s goals and requirements. These needs can be addressed through skills gap assessments and training. Read More ›

Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›

The addition of a novel bispecific antibody to preactivated and expanded natural killer (NK) cells may represent an effective therapy for pretreated patients with relapsed or refractory CD30-positive lymphoma, according to preliminary findings from a phase 1/2 clinical trial presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer. Read More ›

Endocrine therapy after breast-­conserving surgery may be the only treatment needed in patients aged ≥55 years with low-grade luminal type A breast cancer, sparing them radiation therapy, including its side effects, financial burden, and inconvenience, according to findings from the single-arm LUMINA clinical trial reported at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

Cancer growth and oncology care did not stop during the COVID-19 pandemic, and oncologists, healthcare workers, and patients came together to overcome challenges and produce incredible solutions that may be with us for many years. Read More ›

Navigation is still fairly new to the world of urology private practice, but thanks to the efforts of a few navigators who set out to identify and recover genitourinary (GU) oncology patients in need of care or lost to follow-up, navigators have solidified their place as part of the multidisciplinary team at Urology Austin, the largest urology group in Central Texas. Read More ›

International patients seeking cancer treatment in the United States face a number of unique barriers to care, according to Elizabeth Paucar Harris, MBA, chief executive officer at H.O.P.E., Helping Our People Everywhere. Read More ›

Page 1 of 2